The Biotech Company Medendi Closes €1.4 Million Round

Medendi, a digital services platform for oncology, has concluded the raising of €1.4 million, divided equally between equity and debt. The deal is underwritten by entrepreneurs and institutional investors such as Apeiron Holding of the Bonan family, Gama Partecipazioni of Gianmarco Ferrari, GF4BIZ of Guglielmo Fiocchi, Francesca Giubergia, Francesco Porri of Fortop and Recomec, an investment holding company controlled by the Zanelli family. Emil Banca Credito Cooperativo is the partner bank in the ‘matching debt’ financing transaction, guaranteed by MCC, to support the investment.

Medendi has been active since February 2021 and has received more than 1,500 requests for support from Italian cancer patients. The year 2023, thanks to the injection of new resources, will see Medendi’s offerings enriched with new diagnostic services and the organization welcoming new talent, with the mission to support patients and oncologists even more effectively. This development phase will serve to lay the groundwork for expansion into other European countries, particularly Spain and Germany.

If you want to find more details about Medendi and read the latest financial news of the day, download for free our companion app Born2Invest.

Details of Medendi’s round

Medendi’s fundraising will continue during 2023, with the goal of further increasing resources to support the launch of new services and the internationalization of the project.

“To have succeeded in just a few months, thanks to a package of services and a fully digital patient acquisition system, to become a point of reference for so many patients and oncologists in every part of Italy is truly a great success for a young company like ours that is not yet well known by the general public,” said Giorgio Pasetto, founder and CEO of Medendi.

The financing round will enable Medendi help more patients

Maurizio Scaltriti, Founder and Chairman of the Scientific Committee of Medendi and Vice President of Translational Medicine, Early Oncology TDE of AstraZeneca, USA, added, “Medendi’s goal is to help oncology patients to easily and quickly access the best of innovation and research in oncology and precision medicine. This deal will enable us to support more patients and oncologists with increasingly advanced services and diagnostics and broaden the scope of our services to prevention and post-therapy monitoring of cancer patients.”

In the activities of negotiating and finalizing the investment contract, as well as the shareholders’ agreements, Medendi was assisted for legal profiles by Uno Quattro Studio Legale of Milan, with a team led by Attorney Corrado Blandini. Francesco Inguscio with Rainmakers acted as Medendi’s financial advisor. DLA PIPER Studio Legale Tributario Associato assisted Medendi in its due diligence activities with a team led by Attorneys Danilo Surdi and Carlos Rosquet Martinez.

__

(Featured image by fototommy via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in StartupItalia, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.